Dmitry Balyasny’s ProQR Therapeutics PRQR Stock Holding History

Dmitry Balyasny’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21,433	Closed	-$16K	–	3141
2022 Q3	$16K	Buy	+21,433	New	+$17.2K	﹤0.01%	2602
2021 Q3	–	Sell	-130,000	Closed	-$876K	–	2327
2021 Q2	$876K	Buy	+130,000	New	+$838K	﹤0.01%	1346

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $47.2M AUM 32.31% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dmitry Balyasny's PRQR Position: Q4 2022 in Review

Dmitry Balyasny sold out of ProQR Therapeutics (PRQR) in Q4 2022, closing a stake of 21,433 shares — an estimated $16K sold.

Dmitry Balyasny first reported a position in PRQR in Q2 2021 and held it in 2 quarters. The position peaked at $876K in Q2 2021. 46 funds tracked by Wall St. Rank hold PRQR as of Q4 2022.

Dmitry Balyasny reported no remaining ProQR Therapeutics position as of Q4 2022 after selling out during the quarter.
Dmitry Balyasny sold 21,433 ProQR Therapeutics shares in Q4 2022, an estimated $16K.
Dmitry Balyasny first reported a position in ProQR Therapeutics in Q2 2021 and held it in 2 quarters.
Dmitry Balyasny's ProQR Therapeutics position peaked at $876K in Q2 2021.
46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.